Abstract
Background: Nitric oxide (NO) is a potential biochemical, cardio-metabolic risk marker. The production of NO is catalyzed by different isoforms of enzymes, NO synthases (NOS). An altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Activity of NOS and NO production are regulated by various hormones under physiological and pathophysiological condition.
Methods: Data used for this review were obtained by searching the electronic database [PUBMED/MEDLINE 1984 - May 2016]. Additionally, abstracts from national and international diabetes and cardiovascular related meetings were searched. The main data search terms were: nitric oxide, nitric oxide synthase, cardio-metabolic risk, obesity, diabetes, cardiovascular disease, estradiol and insulin-like growth factor-1. Results: In this review, we summarize the recent literature data related to the regulation of endothelial NOS (eNOS), inducible (iNOS) activity/expression, and thereby NO production by the hormones: estradiol (E2), and insulin-like growth factor-1 (IGF-1). Conclusion: Understanding the regulation of NO production by different hormones such as E2, and IGF-1 may provide novel and useful knowledge regarding how endothelial dysfunction (ED) is linked with cardio-metabolic alterations and diseases.Keywords: Nitric oxide, nitric oxide synthase, cardio-metabolic risk, estradiol, insulin-like growth factor-1.
Current Pharmaceutical Design
Title:Hormonal Regulation of Nitric Oxide (NO) in Cardio-metabolic Diseases
Volume: 23 Issue: 10
Author(s): Emina Sudar-Milovanovic, Sonja Zafirovic, Aleksandra Jovanovic, Jovana Trebaljevac, Milan Obradovic, Desanka Cenic-Milosevic and Esma R. Isenovic*
Affiliation:
- Vinca Institute of Nuclear Sciences, University of Belgrade, Laboratory of Radiobiology and Molecular Genetics, P.O.Box 522, 11000 Belgrade,Serbia
Keywords: Nitric oxide, nitric oxide synthase, cardio-metabolic risk, estradiol, insulin-like growth factor-1.
Abstract: Background: Nitric oxide (NO) is a potential biochemical, cardio-metabolic risk marker. The production of NO is catalyzed by different isoforms of enzymes, NO synthases (NOS). An altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Activity of NOS and NO production are regulated by various hormones under physiological and pathophysiological condition.
Methods: Data used for this review were obtained by searching the electronic database [PUBMED/MEDLINE 1984 - May 2016]. Additionally, abstracts from national and international diabetes and cardiovascular related meetings were searched. The main data search terms were: nitric oxide, nitric oxide synthase, cardio-metabolic risk, obesity, diabetes, cardiovascular disease, estradiol and insulin-like growth factor-1. Results: In this review, we summarize the recent literature data related to the regulation of endothelial NOS (eNOS), inducible (iNOS) activity/expression, and thereby NO production by the hormones: estradiol (E2), and insulin-like growth factor-1 (IGF-1). Conclusion: Understanding the regulation of NO production by different hormones such as E2, and IGF-1 may provide novel and useful knowledge regarding how endothelial dysfunction (ED) is linked with cardio-metabolic alterations and diseases.Export Options
About this article
Cite this article as:
Sudar-Milovanovic Emina, Zafirovic Sonja, Jovanovic Aleksandra, Trebaljevac Jovana, Obradovic Milan, Cenic-Milosevic Desanka and Isenovic R. Esma*, Hormonal Regulation of Nitric Oxide (NO) in Cardio-metabolic Diseases, Current Pharmaceutical Design 2017; 23 (10) . https://dx.doi.org/10.2174/1381612823666170124124855
DOI https://dx.doi.org/10.2174/1381612823666170124124855 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Cardiac Antihypertrophic Effects of Cyclic GMP-Generating Agents: An Experimental Framework for Novel Treatments of Left Ventricular Remodeling
Vascular Disease Prevention (Discontinued) Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Current Cardiology Reviews Regulation of Brain Reward by the Endocannabinoid System: A Critical Review of Behavioral Studies in Animals
Current Pharmaceutical Design Effects of Natural Compounds on Xenopus Embryogenesis: A Potential Read Out for Functional Drug Discovery Targeting Wnt/β-catenin Signaling
Current Topics in Medicinal Chemistry Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer
Current Pharmaceutical Design Neuroprotective Appraisal of Methanolic Extract of Flowers of Nerium oleander in a Non Classical Rat Model of Alzheimer Disease
The Natural Products Journal Validated Spectrodensitometric Method for Simultaneous Estimation of Sofosbuvir, Ribavirin and Saxagliptin in their Pure and Pharmaceutical Dosage Forms
Current Pharmaceutical Analysis Consumption of Mixed Fruit-juice Drink and Vitamin C Reduces Postprandial Stress Induced by a High Fat Meal in Healthy Overweight Subjects
Current Pharmaceutical Design Inflammation and Arterial Hypertension: From Pathophysiological Links to Risk Prediction
Current Medicinal Chemistry Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Clinical Presentation, Diagnostic Work-Up, and Treatment of Coronary In-Stent Restenosis
Vascular Disease Prevention (Discontinued) Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations
Current Pharmaceutical Design Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care
Current Hypertension Reviews MicroRNA-16-5p Aggravates Myocardial Infarction Injury by Targeting the Expression of Insulin Receptor Substrates 1 and Mediating Myocardial Apoptosis and Angiogenesis
Current Neurovascular Research Re-Centering Diabetes Care through Community: The iHealthSpace Example
Current Diabetes Reviews The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets Plasma Non-cholesterol Sterols as Markers of Cholesterol Synthesis and Intestinal Absorption: A Critical Review
Current Pharmaceutical Design Gastric Bypass and Diabetes: Past, Present and Future
Current Diabetes Reviews Delivery Systems for Biopharmaceuticals. Part I: Nanoparticles and Microparticles
Current Pharmaceutical Biotechnology